In solution-phase manufacture of D-valine-containing peptide active pharmaceutical ingredients, CBZ-D-valine is activated either through a mixed anhydride sequence or through carbodiimide-mediated coupling. The mixed anhydride route uses isobutyl chloroformate and N-methylmorpholine in anhydrous tetrahydrofuran at −15 °C to −5 °C. Below −15 °C, the mixed anhydride separates as a viscous oil, while above −5 °C, disproportionation to the symmetric anhydride accelerates C-terminal epimerization. The activated species is added to the amine hydrochloride containing 1.0 equivalent of N-methylmorpholine to liberate the free amine. A typical stoichiometry charges CBZ-D-valine at 1.05–1.10 molar equivalents relative to the amine hydrochloride because the Cbz carbamate nitrogen consumes additional base during activation. Coupling conversion is monitored by C18 HPLC area percent, with in-process control accepting <2.0 % residual CBZ-D-valine before the ethyl acetate/sodium chloride wash sequence. After coupling, the protected peptide is isolated from the aqueous dimethylformamide layer by extraction. The Cbz group is removed by hydrogenolysis over 5 % Pd/C or 10 % Pd/C under 0.1–0.3 MPa hydrogen in ethanol/water at 25–40 °C. This hydrogenation step is incompatible with sulfur-containing residues because thioether groups poison the palladium surface. For methionine-containing sequences, catalytic transfer hydrogenation with ammonium formate is used, but the transfer method releases ammonia and can cleave formate-labile protecting groups. The resulting unprotected D-valine peptide is purified by reversed-phase C18 preparative chromatography with acetonitrile/0.1 % trifluoroacetic acid mobile phases. Residual palladium is controlled below 5 µg/g by ICP-MS after a charcoal depth filter pass. The terminal peptide fragments are used in metabolically stabilized peptide drug substances in which inversion of the valine alpha-carbon from L- to D-configuration reduces aminopeptidase N cleavage rates. No globally harmonized pharmacopoeial monograph exists for CBZ-D-valine; release under ICH Q7 is expected for GMP peptide campaigns. Batch-to-batch variance in the free acid content is controlled by titration within 98.0–101.0 %, and residual D-valine is held below 0.5 % by HPLC with evaporative light scattering detection.

Does the Cbz Group Offer Hydrogenolytic Orthogonality in D-Valine Methyl Ester Hydrochloride Processing?

For manufacture of D-valine methyl ester hydrochloride, CBZ-D-valine is first esterified with thionyl chloride in methanol at 0–5 °C. The molar ratio of thionyl chloride to CBZ-D-valine is commonly 1.2–1.5; residual sulfite compounds are neutralized with sodium bicarbonate to prevent acid-catalyzed cleavage of the Cbz group during aging. Esterification is held for 6–10 h, with conversion exceeding 98 % measured by gas chromatography on a nonpolar capillary column. The resulting Cbz-D-valine methyl ester is extracted into methyl tert-butyl ether and crystallized from n-hexane at −10 °C to −5 °C. Hydrogenolysis is conducted in methanol or ethanol at 0.2–0.4 MPa hydrogen over 5 % Pd/C with an agitator tip speed of 2.0–3.0 m/s. Toluene generated by Cbz cleavage is removed by vacuum distillation and must be below 890 ppm in the final product according to ICH Q3C Class 2 residual solvent limits. The free amino ester is liberated by neutralizing the hydrochloride with aqueous potassium carbonate in methyl tert-butyl ether; the organic layer is dried over molecular sieves 4A and the product is isolated as the hydrochloride by bubbling anhydrous hydrogen chloride gas at 0 °C. Final D-valine methyl ester hydrochloride is controlled for D/L ratio below 0.5 % by chiral HPLC on a zwitterionic chiral stationary phase. This building block is then used in N-arylation for agrochemical actives and in peptide substrate manufacturing. Incompatibility is significant: hydrogenation with sulfur-containing solvents or thiol additives reduces catalyst turnover, and tetrahydrothiophene poisoning is considered irreversible above 50 ppm. Published process data for CBZ-D-valine hydrogenolysis in this specific ester configuration is available mainly from pilot-scale batch records rather than from formal peer-reviewed studies.

When Cbz-D-Valine Is Applied as the Terminal Residue in Fmoc/tBu Solid-Phase Synthesis

CBZ-D-valine can be introduced as the final N-terminal amino acid in Fmoc/tBu solid-phase peptide synthesis. In this route, the peptide chain is assembled on Wang resin at a substitution of 0.4–0.6 mmol/g. Chain elongation uses standard 20 % piperidine in dimethylformamide for Fmoc removal. At the final cycle, after Fmoc deprotection, CBZ-D-valine is coupled with HATU and N,N-diisopropylethylamine in dimethylformamide at 0.35 M concentration. The coupling time is 2–4 h under inert atmosphere. The molar excess of CBZ-D-valine relative to resin free amine is 3–5 equivalents, with HATU at 3–5 equivalents and N,N-diisopropylethylamine at 6–10 equivalents. A Kaiser test negative endpoint is targeted; if a positive colour persists after 4 h, a second coupling with 2 equivalents CBZ-D-valine, 2 equivalents HATU, and 4 equivalents N,N-diisopropylethylamine is performed. The Cbz group remains stable during the final TFA cleavage cocktail, typically TFA/triisopropylsilane/water at 95:2.5:2.5 v/v/v for 2–3 h. The crude peptide retains N-terminal Cbz protection until reversed-phase purification, which improves chromatographic resolution by reducing positive charge at the N-terminus and permitting a steeper acetonitrile gradient. After purification, the Cbz group is removed by hydrogenolysis over 5 % Pd/C in acetic acid/water at 20–30 °C; if the peptide sequence contains methionine or cysteine, hydrogenolysis is replaced by hydrogen bromide in acetic acid at 0 °C, which introduces a risk of acidolytic degradation of tryptophan residues. The terminal product is an unprotected peptide with a D-valine N-terminus, used in antimicrobial peptide drug discovery and cyclic peptide analog synthesis. Process limitations include resin batch-to-batch swelling variance in dichloromethane versus dimethylformamide; 2-chlorotrityl chloride resin shows a volume increase up to 6–8 mL/g in dichloromethane, requiring reactor freeboard capacity beyond 25 % of the working volume.

D-Valine Anilino Acid Intermediates Feed Acaricide Synthesis in Agrochemical Manufacturing

D-valine methyl ester hydrochloride derived from CBZ-D-valine is converted to (2R)-2-[2-chloro-4-(trifluoromethyl)anilino]-3-methylbutanoic acid, the chiral acid fragment of tau-fluvalinate. The N-arylation step uses palladium-catalyzed Buchwald-Hartwig coupling between D-valine methyl ester free base and 2-chloro-4-(trifluoromethyl)aniline in toluene at 80–90 °C with sodium tert-butoxide or cesium carbonate as base, palladium(II) acetate at 0.5–1.0 mol %, and racemic BINAP at 0.8–1.5 mol %. The aryl amine is charged at 1.10–1.20 equivalents relative to D-valine methyl ester to account for slow oxidative addition of the electron-poor aryl chloride. Reaction completion requires 12–18 h; conversion below 95 % after this period typically indicates moisture ingress above 500 ppm in process-grade toluene, which hydrolyzes the catalyst-ligand complex. After aqueous workup, the methyl ester is saponified with lithium hydroxide in tetrahydrofuran/water at 20–25 °C. The resulting acid is coupled to (RS)-alpha-cyano-3-phenoxybenzyl alcohol using dicyclohexylcarbodiimide and dimethylaminopyridine in dichloromethane at 0–5 °C. The diastereomeric ratio at the valine-derived C2 centre is controlled above 98:2 because the technical active substance is registered with the valine-derived stereocentre fixed as (2R); the (2S) acid component is reduced by crystallization of the dicyclohexylamine salt from isopropanol. Technical-grade tau-fluvalinate is formulated for mite and insect control on field crops. Compliance for the chiral intermediate in synthetic campaigns follows general agrochemical impurity profiling under OECD guidelines and EU 1107/2009 residue chemistry requirements. Analytical release includes enantiomeric purity by HPLC on chiral stationary phases, residual palladium below 10 µg/g, and moisture below 0.5 %. The process is sensitive to free amino ester concentration; above 0.35 M, catalyst inhibition by the secondary amine substrate increases and conversion stalls below 60 %.

Chiral Auxiliary Derivatization via Cbz-D-Valinol Intermediates

Reduction of CBZ-D-valine to Cbz-D-valinol is performed with sodium borohydride and iodine in tetrahydrofuran at 0–5 °C, using 1.2–1.5 equivalents sodium borohydride and 1.2–1.5 equivalents iodine per equivalent of starting acid. Iodine addition is controlled to keep the internal temperature below 5 °C; excessive iodine causes benzyl carbamate cleavage and loss of the N-protecting group. After aqueous quench with 10 % citric acid, Cbz-D-valinol is extracted into ethyl acetate and crystallized from heptane/toluene. The Cbz group is then removed by hydrogenolysis over 10 % Pd/C in methanol at 0.2 MPa to release D-valinol. D-valinol is converted to chiral oxazoline ligands by condensation with substituted 2-hydroxybenzaldehydes in refluxing toluene with azeotropic water removal; the oxazoline is metallated with copper(I) triflate for asymmetric Henry reaction catalysis. Industrial use of this chemistry is confined to non-GMP fine chemical and process research. Published process safety data for scale-up of the borohydride-iodine reduction of CBZ-D-valine is limited; the reaction is exothermic and should be evaluated with a reaction calorimeter before batch size exceeds 50 kg. The major operational boundary is that borane-iodide reduction releases diborane and must be vented through a caustic scrubber. Batch-to-batch variance arises from iodine purity and the rate of sodium borohydride addition; irregular addition has been observed to form valinol byproducts with incomplete N-protection. The terminal products are chiral oxazoline ligands and D-valinol-derived intermediates for stereoselective catalysis. Quality is governed by ISO 9001 and in-house analytical specifications rather than a compendial monograph.

Racemization risk during CBZ-D-valine activation becomes the primary process limit when the acid is coupled to alpha-hydroxyisovaleric acid in cyclic depsipeptide synthesis. Carbodiimide-mediated activation in dichloromethane must remain below 8 °C; base addition above 1.2 equivalents triggers oxazolone formation and Cα epimerization within minutes. The process uses 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride at 1.05 equivalents, 1-hydroxybenzotriazole hydrate at 1.05 equivalents, and N-methylmorpholine at 1.10 equivalents relative to CBZ-D-valine. The alpha-hydroxy acid is pre-dissolved in dichloromethane and added slowly over 30–45 min to the activated intermediate at 0 °C. The resulting depsipeptide ester is isolated by cold aqueous bicarbonate wash at 0–5 °C; washing with sodium carbonate above pH 9.5 cleaves the depsipeptide ester at approximately 1–2 % per minute, so pH 8.0–8.5 solutions are used. Chiral purity is monitored on an amylose tris(3,5-dimethylphenylcarbamate) column; D/L ratio exceeding 0.8 % triggers reprocessing by crystallization from isopropyl acetate/n-heptane. Storage of the isolated intermediate at −20 °C is required if the next hydrogenation step is delayed beyond 24 h, because the ester linkage undergoes slow acyl migration at room temperature. Terminal products are cyclic depsipeptides used as ionophore analytical reagents and antibiotic research standards. This scenario represents a process conflict zone where a temperature increase of 5 °C above 8 °C produces substantial epimerization; published Arrhenius parameters for this specific substrate are limited, so the reactor thermal control loop should use a jacket with propylene glycol at −10 °C rather than an ice bath.